Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 versus AMINOSYN II 7 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 versus AMINOSYN II 7 W ELECTROLYTES.
AMINOSYN 8.5% vs AMINOSYN II 7% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% is a crystalline amino acid solution that provides a source of nitrogen and essential/non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It serves as a substrate for metabolic pathways, including gluconeogenesis and ketogenesis, and supports immune function and enzyme production.
Provides essential and non-essential amino acids for protein synthesis, promotes nitrogen balance, and serves as a caloric source in parenteral nutrition.
Intravenous infusion: 1.0-1.5 g amino acids/kg/day (11.8-17.6 mL/kg/day of 8.5% solution) via central line; rate not to exceed 0.1 g amino acids/kg/hour.
Adults: 500 mL to 2000 mL/day intravenously via central line at a rate not exceeding 100 mL/hour. Dosage based on protein requirement (0.8-1.5 g/kg/day) and nutritional status.
None Documented
None Documented
Variable; amino acids have rapid distribution and metabolic half-lives of minutes to hours; terminal half-life of infused amino acid mixtures is approximately 1–2 hours for most components in patients with normal hepatic function
Variable; amino acids: 10–40 minutes (rapid distribution and metabolism); clinical context: continuous infusion required to maintain steady state
Renal elimination of infused amino acids as urea, ammonia, and other nitrogenous waste products; minimal biliary/fecal excretion (<2%)
Renal: >80% as amino acids and metabolites; fecal: negligible; biliary: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution